Skip to main content

Table 3 Results of Antibody Measurement

From: Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study

Subject number

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

Cancer

Esoph.

CCA

Rectal

Esoph.

CCA

Pancr.

Gist

Colon

CCA

Coecum

+Ovar.

Pancr.

Pancr.

Bile duct

Rectal

Bile duct

pCCC

Surgery blood (mL)

Dilution fluid (mL)

1400

550

500

0

2800

2500

1600

1000

1100

500

1600

500

800

300

950

300

1000

700

2200

200 + 800

800

150

1700

1400

1661

900

2600

50

1400

100

800

200

EC after LDF, residual Ab (pg/mL)

BLQ

1694

BLQ

BLQ

205.0

BLQ

1026

491.0

ND

252.0

BLQ

888.0

628.0

BLQ

160.0

BLQ

Ab total (ng)

BLQ

69.0

BLQ

BLQ

13.0

BLQ

68.0

22.0

BLQ

27.0

BLQ

59.0

26.0

BLQ

9.0

BLQ

Vol. EC (mL)

142.0

76.0

150.0

98.0

97.0

187.0

101.0

80.0

70.0

141.0

75.0

101.0

77.0

373.0

133.0

–

Vol. EC post LDF (mL)

107.0

41.0

115.0

63.0

62.0

152.0

66.0

45.0

35.0

106.0

40.0

66.0

42.0

320.0

60.0

200.0

Amount of applied antibody (μg)

5.0

2.5

2.5

2.5

2.5

5.0

2.5

2.5

–

5.0

2.5

5.0

5.0

5.0

2.5

2.5

  1. BLQ Below the limit of quantification of 125 pg/mL
  2. Ab Antibody, CCA cholangiocarcinoma, EC Erythrocyte concentrate, Esoph. Esophageal cancer, LDF Leukocyte depletion filter, ND No antibody detectable in the reservoir, Ovar. Ovarian cancer, Pancr. Pancreatic cancer, pCCC Perihilar cholangiocellular carcinoma, Vol. Volume